Table 1. The association of BRAF V600E, RET mutations and clinicopathologic characteristics in papillary thyroid carcinoma (case, %).
| Items | BRAF V600E | RET | |||||
|---|---|---|---|---|---|---|---|
| Mutation (n=55) | wild-type (n=13) | P value | Mutation (n=7) | Wild-type (n=61) | P value | ||
| Sex | 0.670 | ||||||
| Male | 16 (29.1%) | 1 (7.7%) | 0.160 | 1 (14.3%) | 16 (26.2%) | ||
| Female | 39 (70.9%) | 12 (92.3%) | 6 (85.7%) | 45 (73.8%) | |||
| Age at diagnosis, years | |||||||
| Mean ± SD | 40.9±10.2 | 30.2±11.9 | 0.001 | 25.6±12.4 | 40.4±10.2 | 0.001 | |
| <55 | 50 (90.9%) | 13 (100.0%) | 0.575 | 7 (100.0%) | 56 (91.8%) | 1.000 | |
| ≥55 | 5 (9.1%) | 0 (0.0%) | 0 (0.0%) | 5 (8.2%) | |||
| Tumor size in mm | |||||||
| Mean ± SD | 15.1±7.6 | 19.8±11.5 | 0.186 | 17.7±12.0 | 15.8±8.2 | 0.585 | |
| ≤10 | 18 (32.7%) | 3 (23.1%) | 0.740 | 3 (42.9%) | 18 (29.5%) | 0.668 | |
| >10 | 37 (67.3%) | 10 (77.9%) | 4 (57.1%) | 43 (70.5%) | |||
| cN0 | 0.107 | ||||||
| Yes | 30 (54.5%) | 3 (23.1%) | 0.041 | 1 (14.3%) | 32 (52.5%) | ||
| No | 25 (45.5%) | 10 (76.9%) | 6 (85.7%) | 29 (47.5%) | |||
| Location | 0.409 | ||||||
| Upper | 20 (36.4%) | 3 (23.1%) | 0.519 | 1 (14.3%) | 22 (36.1%) | ||
| Middle/lower | 35 (63.6%) | 10 (76.9%) | 6 (85.7%) | 39 (63.9%) | |||
| HT | 0.390 | ||||||
| Yes | 14 (25.5%) | 5 (38.5%) | 0.492 | 3 (42.9%) | 16 (26.2%) | ||
| No | 41 (74.5%) | 8 (61.5%) | 4 (57.1%) | 45 (73.8%) | |||
| ETE | 0.415 | ||||||
| Yes | 38 (69.1%) | 4 (30.8%) | 0.023 | 3 (42.9%) | 39 (63.9%) | ||
| No | 17 (30.9%) | 9 (69.2%) | 4 (57.1%) | 22 (36.1%) | |||
| Multifocality | 1.000 | ||||||
| Yes | 9 (16.4%) | 2 (15.4%) | 1.000 | 1 (14.3%) | 10 (16.4%) | ||
| No | 46 (83.6%) | 11 (84.6%) | 6 (85.7%) | 51 (83.6%) | |||
| LNMN | |||||||
| Mean ± SD | 6.7±6.7 | 10.2±7.0 | 0.090 | 13.0±5.8 | 6.7±6.7 | 0.020 | |
| ≤5 | 27 (49.1%) | 3 (23.1%) | 0.089 | 0 (0.0%) | 30 (49.2%) | 0.015 | |
| >5 | 28 (50.1%) | 10 (76.9%) | 7 (100.0%) | 31 (50.8%) | |||
| CLNM | 1.000 | ||||||
| Yes | 42 (76.4%) | 11 (84.6%) | 0.717 | 6 (85.7%) | 47 (77.0%) | ||
| No | 13 (23.6%) | 2 (15.4%) | 1 (14.3%) | 14 (23.0%) | |||
| LLNM | 0.225 | ||||||
| Yes | 28 (50.9%) | 11 (84.6%) | 0.027 | 6 (85.7%) | 33 (54.1%) | ||
| No | 27 (49.1%) | 2 (15.4%) | 1 (14.3%) | 28 (45.9%) | |||
| Stage | 1.000 | ||||||
| I/II | 53 (96.4%) | 13 (100.0%) | 1.000 | 7 (100.0%) | 59 (96.7%) | ||
| III/IV | 2 (3.6%) | 0 (0.0%) | 0 (0.0%) | 2 (3.3%) | |||
| Risk-group stratification | 0.582 | ||||||
| Low | 7 (12.7%) | 3 (23.1%) | 0.389 | 0 (0.0%) | 10 (16.4%) | ||
| Moderate/high | 48 (87.3%) | 10 (76.9%) | 7 (100.0%) | 51 (83.6%) | |||
cN0, clinical lymph node-negative; HT, Hashimoto’s thyroiditis; ETE, extrathyroidal extension; LNMN, the Metastatic number of lymph nodes; CLNM, central lymph node metastasis; LLNM, lateral lymph node metastasis.